$16.1
Insights on Macrogenics, Inc.
Revenue is up for the last 2 quarters, 10.39M → 11.00M (in $), with an average increase of 5.5% per quarter
Netprofit is down for the last 3 quarters, 57.46M → -45.83M (in $), with an average decrease of 215.3% per quarter
In the last 3 years, Novo Nordisk A/s has given 242.1% return, outperforming this stock by 289.7%
0.43%
Downside
Day's Volatility :4.36%
Upside
3.94%
73.35%
Downside
52 Weeks Volatility :80.39%
Upside
26.42%
Period | Macrogenics, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 58.1% | -0.5% | 0.0% |
6 Months | 216.51% | 5.9% | 0.0% |
1 Year | 144.57% | 3.1% | -1.9% |
3 Years | -47.66% | 14.2% | -21.8% |
Market Capitalization | 1.1B |
Book Value | $2.46 |
Earnings Per Share (EPS) | -0.15 |
PEG Ratio | 0.01 |
Wall Street Target Price | 24.78 |
Profit Margin | -15.42% |
Operating Margin TTM | -460.39% |
Return On Assets TTM | -36.33% |
Return On Equity TTM | -6.15% |
Revenue TTM | 58.7M |
Revenue Per Share TTM | 0.95 |
Quarterly Revenue Growth YOY | -85.3% |
Gross Profit TTM | -62.5M |
EBITDA | -158.6M |
Diluted Eps TTM | -0.15 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.52 |
EPS Estimate Next Year | -2.01 |
EPS Estimate Current Quarter | -0.15 |
EPS Estimate Next Quarter | -0.49 |
What analysts predicted
Upside of 53.91%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 60.1M | ↓ 61.34% |
Net Income | -171.5M | ↑ 773.6% |
Net Profit Margin | -285.18% | ↓ 272.56% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 62.0M | ↑ 3.17% |
Net Income | -151.8M | ↓ 11.46% |
Net Profit Margin | -244.76% | ↑ 40.42% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 97.8M | ↑ 57.62% |
Net Income | -117.8M | ↓ 22.42% |
Net Profit Margin | -120.48% | ↑ 124.28% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 75.6M | ↓ 22.63% |
Net Income | -190.9M | ↑ 62.04% |
Net Profit Margin | -252.31% | ↓ 131.83% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 151.9M | ↑ 100.87% |
Net Income | -120.0M | ↓ 37.11% |
Net Profit Margin | -78.99% | ↑ 173.32% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 58.7M | ↓ 61.33% |
Net Income | -9.1M | ↓ 92.45% |
Net Profit Margin | -15.42% | ↑ 63.57% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 41.7M | ↑ 60.47% |
Net Income | -24.7M | ↓ 39.53% |
Net Profit Margin | -59.11% | ↑ 97.77% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 71.2M | ↑ 70.55% |
Net Income | 12.8M | ↓ 151.89% |
Net Profit Margin | 17.99% | ↑ 77.1% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 24.2M | ↓ 65.98% |
Net Income | -38.2M | ↓ 398.77% |
Net Profit Margin | -157.96% | ↓ 175.95% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 13.1M | ↓ 45.75% |
Net Income | 57.5M | ↓ 250.25% |
Net Profit Margin | 437.49% | ↑ 595.45% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 10.4M | ↓ 20.85% |
Net Income | 17.6M | ↓ 69.45% |
Net Profit Margin | 168.84% | ↓ 268.65% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 11.0M | ↑ 5.83% |
Net Income | -45.8M | ↓ 361.1% |
Net Profit Margin | -416.55% | ↓ 585.39% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 332.1M | ↓ 11.17% |
Total Liabilities | 89.3M | ↑ 19.57% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 312.5M | ↓ 5.91% |
Total Liabilities | 81.9M | ↓ 8.27% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 378.7M | ↑ 21.2% |
Total Liabilities | 82.9M | ↑ 1.2% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 335.2M | ↓ 11.48% |
Total Liabilities | 95.6M | ↑ 15.41% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 280.5M | ↓ 16.34% |
Total Liabilities | 138.5M | ↑ 44.79% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 298.4M | ↑ 6.4% |
Total Liabilities | 145.8M | ↑ 5.31% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 195.3M | ↓ 10.41% |
Total Liabilities | 72.4M | ↓ 4.2% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 280.5M | ↑ 43.57% |
Total Liabilities | 138.5M | ↑ 91.27% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 343.5M | ↑ 22.47% |
Total Liabilities | 234.2M | ↑ 69.17% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 305.7M | ↓ 11.02% |
Total Liabilities | 134.1M | ↓ 42.74% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 340.0M | ↑ 11.23% |
Total Liabilities | 146.0M | ↑ 8.86% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 298.4M | ↓ 12.22% |
Total Liabilities | 145.8M | ↓ 0.13% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -153.2M | ↓ 1163.76% |
Investing Cash Flow | 56.6M | ↓ 27.26% |
Financing Cash Flow | 105.0M | ↑ 197.02% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -134.3M | ↓ 12.38% |
Investing Cash Flow | -79.4M | ↓ 240.1% |
Financing Cash Flow | 120.0M | ↑ 14.27% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -111.9M | ↓ 16.66% |
Investing Cash Flow | -7.8M | ↓ 90.19% |
Financing Cash Flow | 174.3M | ↑ 45.32% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -143.8M | ↑ 28.54% |
Investing Cash Flow | -36.6M | ↑ 370.25% |
Financing Cash Flow | 122.8M | ↓ 29.58% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -87.0M | ↓ 39.54% |
Investing Cash Flow | 70.7M | ↓ 293.16% |
Financing Cash Flow | 1.7M | ↓ 98.65% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -9.4M | ↓ 80.83% |
Investing Cash Flow | 71.9M | ↑ 212.28% |
Financing Cash Flow | -14.0K | ↓ 105.32% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 29.3M | ↓ 411.19% |
Investing Cash Flow | -5.8M | ↓ 108.04% |
Financing Cash Flow | 1.4M | ↓ 9807.14% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -12.8M | ↓ 143.77% |
Investing Cash Flow | 28.1M | ↓ 585.4% |
Financing Cash Flow | 100.1M | ↑ 7267.03% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.1M | ↓ 83.72% |
Investing Cash Flow | -113.5M | ↓ 503.9% |
Financing Cash Flow | 59.0K | ↓ 99.94% |
Sell
Neutral
Buy
Macrogenics, Inc. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Macrogenics, Inc. | 6.92% | 216.51% | 144.57% | -47.66% | 2.02% |
Moderna, Inc. | -0.45% | 20.22% | -27.91% | -35.9% | 341.66% |
Regeneron Pharmaceuticals, Inc. | -6.85% | 6.85% | 9.08% | 78.94% | 160.71% |
Novo Nordisk A/s | -7.1% | 22.03% | 44.33% | 239.61% | 408.97% |
Vertex Pharmaceuticals Incorporated | -4.18% | 5.53% | 20.27% | 79.84% | 136.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Macrogenics, Inc. | 25.32 | NA | 0.01 | -2.52 | -0.06 | -0.36 | NA | 2.46 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.21 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.84 | 25.84 | 1.46 | 45.15 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.75 | 46.75 | 2.4 | 3.36 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.57 | 28.57 | 0.53 | 16.72 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Macrogenics, Inc. | Buy | $1.1B | 2.02% | 25.32 | -15.42% |
Moderna, Inc. | Buy | $40.3B | 341.66% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.6B | 160.71% | 25.84 | 30.14% |
Novo Nordisk A/s | Buy | $559.8B | 408.97% | 46.75 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $102.7B | 136.07% | 28.57 | 36.68% |
Bellevue Group AG
BlackRock Inc
T. Rowe Price Investment Management,Inc.
Armistice Capital, LLC
Vanguard Group Inc
RA Capital Management, LLC
a career at macrogenics could be waiting for you! please click on "careers" ---------------------------->>> to learn more. macrogenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. macrogenics creates both differentiated molecules that are directed to novel cancer targets, as well as “bio-betters,” which are drugs designed to improve upon marketed medicines. the combination of macrogenics’ technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. these are exciting times at macrogenics and we hope that you will take the opportunity to learn more about our organization, our pipeline and to view our job opportunities!
Organization | Macrogenics, Inc. |
Employees | 339 |
CEO | Dr. Scott Koenig M.D., Ph.D. |
Industry | Health Technology |